A cluster of recent studies has sharpened the scientific picture of how T cells switch on, tracking the molecular signals that launch immune responses with resolution measured in seconds. By combining ...
Cooperation between Finnish and Chinese research groups has opened up new opportunities for developing treatments targeting aggressive acute lymphoblastic leukaemia (T-ALL). A research group led by ...
Chimeric antigen receptor (CAR) T cell-based therapy has greatly improved cancer treatment, especially for hematologic cancers. 1 By providing T cells with synthetic receptors that target tumor ...
Researchers at the Keck School of Medicine of University of Southern California (USC) have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response ...
Researchers from the Keck School of Medicine of USC have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response to cancer in mice—effectively ...
CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...
This review explains how glucose scarcity, lipid disruption, amino acid deprivation, and toxic metabolites weaken CAR-T cells ...
EvolveImmune Therapeutics, a clinical-stage immuno-oncology company developing a new class of multi-specific T cell engagers wi ...
Weill Cornell Medicine investigators made an unexpected finding about how the immune system normally suppresses inappropriate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results